1.Study on Intervention Rule on Traditional Chinese Medicine External Treatment of Primary Dysmenorrhea
Yan SHI ; Lijian PANG ; Chuang LIU ; Yongming LIU ; Yantong LIU ; Sihan WANG ; Xiaodong LV
World Science and Technology-Modernization of Traditional Chinese Medicine 2017;19(3):408-413
This study was aimed to analyze and summarize the intervention rule on traditional Chinese medicine (TCM) external treatment of primary dysmenorrhea,in order to provide theoretical evidences for clinical treatment.Articles on TCM external treatment of primary dysmenorrhea published both at home and abroad were search in the CNKI from January Ft,2014 to January Ft,2017.After standard screening,the frequency analysis,cluster analysis and association analysis were conducted.The results showed that acupuncture was the mostly used TCM external treatment of primary dysmenorrhea,which was far more than other types of TCM external treatments.Theoretical studies on single usie of acupuncture or single use of moxibustion were far more than clinical trials.The acupoint used with the highest frequency in primary dysmenorrhea treatment was SP-6 Sanyinjiao.RN-4 Guanyuan was the second and SP-8 Diji was the third.A total of 22 classic acupoint combinations were identified.It was concluded that the main external intervention method of primary dysmenorrhea was acupuncture with SP-6,RN-4 and SP-8 as its main acupoints.There are a total of 22 classic acupoint combinations
2.Engineering the C4 pathway of Corynebacterium glutamicum for efficient production of 5-aminolevulinic acid.
Lijun WANG ; Sihan YAN ; Taowei YANG ; Meijuan XU ; Xian ZHANG ; Minglong SHAO ; Huazhong LI ; Zhiming RAO
Chinese Journal of Biotechnology 2021;37(12):4314-4328
5-aminolevulinic acid (5-ALA) plays an important role in the fields of medicine and agriculture. 5-ALA can be produced by engineered Escherichia coli and Corynebacterium glutamicum. We systematically engineered the C4 metabolic pathway of C. glutamicum to further improve its ability to produce 5-ALA. Firstly, the hemA gene encoding 5-ALA synthase (ALAS) from Rhodobacter capsulatus and Rhodopseudomonas palustris were heterologously expressed in C. glutamicum, respectively. The RphemA gene of R. palustris which showed relatively high enzyme activity was selected. Screening of the optimal ribosome binding site sequence RBS5 significantly increased the activity of RphemA. The ALAS activity of the recombinant strain reached (221.87±3.10) U/mg and 5-ALA production increased by 14.3%. Subsequently, knocking out genes encoding α-ketoglutarate dehydrogenase inhibitor protein (odhI) and succinate dehydrogenase (sdhA) increased the flux of succinyl CoA towards the production of 5-ALA. Moreover, inhibiting the expression of hemB by means of sRNA reduced the degradation of 5-ALA, while overexpressing the cysteine/O-acetylserine transporter eamA increased the output efficiency of intracellular 5-ALA. Shake flask fermentation using the engineered strain C. glutamicum 13032/∆odhI/∆sdhA-sRNAhemB- RBS5RphemA-eamA resulted in a yield of 11.90 g/L, which was 57% higher than that of the original strain. Fed-batch fermentation using the engineered strain in a 5 L fermenter produced 25.05 g/L of 5-ALA within 48 h, which is the highest reported-to-date yield of 5-ALA from glucose.
Aminolevulinic Acid/metabolism*
;
Corynebacterium glutamicum/metabolism*
;
Fermentation
;
Metabolic Engineering
;
Rhodobacter capsulatus/enzymology*
;
Rhodopseudomonas/enzymology*
3.Fitting Degrees of Cathartic Colon Animal Models with Disease Characteristics of Western Medicine and Syndrome Characteristics of Traditional Chinese Medicine
Youcheng HE ; Fengru JIANG ; Yan ZHOU ; Jianan QIAN ; Jun LIU ; Lu HANG ; Chunyu ZHOU ; Sihan LI ; Minghan HUANG ; Jianye YUAN
Chinese Journal of Experimental Traditional Medical Formulae 2023;29(22):146-154
Cathartic colon (CC) is a common and refractory digestive system disease, with the pathogenesis not fully clarified. The effective therapies other than laxatives and surgery remain to be developed for CC. Therefore, establishing the CC animal models that fit the disease characteristics of western medicine and syndrome characteristics of traditional Chinese medicine (TCM) is an important link to promote the research on this disease. The fitting degree of animal models with the latest Chinese and western medical diagnostic criteria is an indicator to assess the effectiveness of the animal models in simulating the disease characteristics of western medicine and syndrome characteristics of TCM. The literature review showed that the model animals, drugs and their dosage forms, doses, administration methods, and modeling period of CC varied in different studies, and the available CC animal models presented different fitting degrees with the disease characteristics of western medicine and syndrome characteristics of TCM. Rats were the preferred animals for the modeling of CC. Rhei Radix et Rhizoma preparations were commonly used for model inducing, which, however, may cause water electrolyte disorders, decreased immunity, and even death of animals at the late stage of modeling. The animals were modeled by gradually increasing the starting dose, while the starting dose and increasing dose varied. The maintenance dose was determined based on 50% of the animals having loose stools, and the end for a cycle was determined as the time when loose stools disappeared in 80% of animals. The modeling always lasted for 2-3 cycles, approximately 2-4 months. The CC models established with Rhei Radix et Rhizoma granules and rhein had high fitting degrees with the disease and syndrome characteristics. In addition, the CC animal models of TCM syndromes were still in the exploration stage. There were only the animal models of four TCM syndromes: liver depression and spleen deficiency, both Qi and Yin deficiency, Qi stagnation and blood stasis, and spleen and kidney deficiency. Efforts should be made to establish the animal models that meet the characteristics of disease of western medicine and syndromes of TCM, so as to facilitate the research on CC mechanism and drug development.